youbet
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
I'm saying that the system is broken if a drug that negatively affects "a whole lot of people" gets reported as 1 in 20 thousand.
Just amplifying on the difficulty of understanding all the numbers and of differentiating anecdotal examples from statistical terms such as "a whole lot of people," I'll mention that the 1 in 20 thousand refers to folks who have muscle and kidney damage due to the statin. Not just to folks who complain of muscle soreness or weakness to some extent or the other while on the statin.
from the Mayo site and my earlier post:
Muscle aching/stiffness
5 in 100 patients
(some need to stop statins because of this);
Muscle and kidney damage
1 in 20,000 patients
(requires patients to stop statins).
I'm lost in the whole thing. And the fact that I'm simultaneously sketchy on the "1 in 20.000" vs. "5 in 100" numbers and folks including terms like "a whole lot of people" with the first group doesn't help.
As I mentioned in an earlier post, blood thinners like Xarelto seem to have similar positions to statins in the drug hierarchy: small percentages of absolute improvement vs. some folks experiencing negative side effects or having traumas. The difference being that statins sometimes seem to be prescribed for folks having few/no symptoms while the blood thinners seem to be focused on folks with an observed issue.
I'm not defending statins, their inventors/manufacturers or the docs who prescribe them in any way. But I am trying to understand the difference between inconveniences such as temporary muscle soreness or a craving for carbs resulting in weight gain and permanent damage to my body. Holding up some members of the "5 in 100" group as members of the "1 in 20,000" group doesn't help.
What a pita this all is!
Last edited: